Clik here to view.
Neuboron Medtech, a BNCT Total Solution Provider, Enters Joint-Venture...
NANJING, China Neuboron Therapy System (NTS), a wholly owned subsidiary of Neuboron Medtech, announced today it has approved an approximate USD 10 million of minority equity investment from TAE Life...
View ArticleClik here to view.
Sherlock Biosciences Strengthens Intellectual Property Portfolio in...
CAMBRIDGE, Mass. Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced exclusive license agreements with...
View ArticleClik here to view.
BeiGene Announces Data on BRUKINSA® (Zanubrutinib) from Phase 2 Trial in...
CAMBRIDGE, Mass. & BEIJING BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today...
View ArticleClik here to view.
Veristat Named Top Patient Recruitment Company 2020 by Pharma Tech Outlook
SOUTHBOROUGH, Mass. Veristat, a global clinical research organization, was named among the Top Patient Recruitment Companies of 2020 by Pharma Tech Outlook. With over 26 years’ experience partnering...
View ArticleClik here to view.
Takeda Presents Real-World Evidence at ASH 2020, Demonstrating Its...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented five hematology poster presentations and four abstracts at the 62nd...
View ArticleClik here to view.
BeiGene Presents Clinical Data on BRUKINSA® (Zanubrutinib) in B-Cell...
CAMBRIDGE, Mass. & BEIJING BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today...
View ArticleClik here to view.
Rhizen Pharmaceuticals SA宣布在美国血液学会(ASH) 2020年会上呈报Tenalisib...
瑞士拉绍德封 (美国商业资讯)–专攻肿瘤学的临床阶段生物制药公司Rhizen Pharmaceuticals今天宣布，将在2020年12月5日至8日召开的美国血液病学会(ASH)第62届视频年会和展会上呈报Tenalisib联合Romidepsin治疗复发/难治T细胞淋巴瘤患者I/II期研究的中期结果。...
View ArticleClik here to view.
Kubota Vision Announces Submission of Novel VAP-1 Inhibitors to the NCI...
SEATTLE Kubota Vision Inc. (“Kubota Vision”), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today...
View ArticleClik here to view.
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for...
BEIJING & CAMBRIDGE, Mass. BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today...
View ArticleClik here to view.
InnoCare Presents Latest Clinical Data of Orelabrutinib at the 62nd Annual...
BEIJING InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today three presentations of the most recent clinical data with orelabrutinib, its BTK inhibitor, at the 62nd...
View ArticleClik here to view.
TAE Life Sciences and Neuboron Medtech Announce Joint Venture Aimed at...
FOOTHILL RANCH, Calif. TAE Life Sciences (TLS) today announces a new joint venture (JV) agreement with Neuboron Medtech (Neuboron) for the widespread adoption of Accelerator-based Boron Neutron...
View ArticleClik here to view.
Rhizen...
スイス・ラショードフォン （ビジネスワイヤ） — オンコロジー分野に傾注する臨床段階のバイオ製薬企業であるRhizen Pharmaceuticalsは本日、来る2020年12月5～8日にバーチャル開催される第62回米国血液学会（ASH）年次大会・展示会で、再発性／難治性T細胞リンパ腫患者でテナリシブとロミデプシンの併用療法を検討する第1／2相試験の中間結果を報告すると発表しました。...
View ArticleClik here to view.
Arcus Biosciences Expands Strategic Relationship with WuXi Biologics to...
HAYWARD, Calif. Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, and WuXi Biologics (2269.HK), a global company...
View ArticleClik here to view.
Results from First Combination Trial of ENHERTU® and Immune Checkpoint...
TOKYO & BASKING RIDGE, N.J. & MUNICH Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today presented the first immunotherapy combination study results for ENHERTU®...
View ArticleClik here to view.
ENHERTU® Continues to Demonstrate Durable Responses with New Data from...
TOKYO, MUNICH & BASKING RIDGE, N.J. Updated results from the positive phase 2 DESTINY-Breast01 trial show Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU®...
View ArticleClik here to view.
武田在ASH 2020上呈报真实世界证据，展现其对罕见出血性障碍个体化治疗的长期承诺
马萨诸塞州剑桥和日本大阪 武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE: 4502/NYSE:TAK)（“武田”）今天在美国血液学会(ASH)第62届年会暨展会上呈报5篇血液学壁报和4篇摘要，强调了其促进罕见出血性障碍治疗的承诺。武田还将在会上呈报其更强大的肿瘤产品阵容和产品管线。在这里阅读更多内容，请点击此处。...
View ArticleClik here to view.
Complimentary Ticket to Join YAFO ACCESS CHINA Forum 2021
SHANGHAI YAFO Life Science and BioToChina.org announced the schedule for ACCESS CHINA Forum 2021 (January 4th - 22nd). As the largest China corporate access event during the JPM Conference weeks,...
View ArticleClik here to view.
Researchers Use Masimo ORi™, Oxygen Reserve Index, to Help Suppress...
NEUCHATEL, Switzerland Masimo (NASDAQ: MASI) announced today the findings of an abstract recently presented at Euroanaesthesia 2020 in which Dr. Kumagai and colleagues at Iwate Medical University...
View ArticleClik here to view.
EdiGene Expands Management Team by Appointment of Head of US Subsidiary Dr....
BEIJING & CAMBRIDGE, Mass. EdiGene, Inc., which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced...
View ArticleClik here to view.
Can-Fite Reports on Progress With Its Namodenoson NASH Program
PETACH TIKVA, Israel Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and...
View Article